Pharmaceuticals company Strides Pharma Science announced Q3FY26 results Revenue at Rs 11,946 million, grew 3.6% YoY. Absolute gross margin at Rs 7,317 million, grew 8.6% YoY. Gross margin improved to 61.2%, up 280bps YoY. EBITDA grew 12.2% YoY to Rs 2,359 million, EBITDA margin at 19.8%, grew 160bps YoY. Ex-US Market Revenue at USD 64 million, reported a strong growth of 20% YoY. Operational PAT at Rs 1,282 million, Grew 38.6% YoY. Operational EPS at Rs 13.9. Reported PAT at Rs 2,081 million. Badree Komandur, MD & Group CEO, said: “Strides continues to deliver a strong performance in Q3FY26 with growth primarily driven by the Other Regulated Markets and Growth Markets. Our strong focus on profitability resulted in gross margin expansion of 280bps YoY, and EBITDA margin increase of 160bps YoY to 19.8%. Operational PAT and Operational EPS registered a growth of ~38% YoY. This performance demonstrates our consistent execution as we continue to invest in sustainable, longterm growth. We are also delighted to welcome Peter Hardwick as the CEO of our North America business. His leadership experience, along with strategic insights of the region, will play a key role in driving our long term growth. Our ongoing commitment to ESG continues to be recognised, with an improved S&P; Global Corporate Sustainability Assessment score of 80, marking a 5 point increase over the previous year.” Result PDF